Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - lenalidomide hydrochloride monohydrate, quantity: 3.025 mg - capsule - excipient ingredients: gelatin; indigo blue; croscarmellose sodium; purified talc; colloidal anhydrous silica; microcrystalline cellulose; iron oxide yellow; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm),te-lenalidomide is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),te-lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - lenalidomide hydrochloride monohydrate, quantity: 9.075 mg - capsule - excipient ingredients: titanium dioxide; microcrystalline cellulose; gelatin; colloidal anhydrous silica; croscarmellose sodium; purified talc; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm),te-lenalidomide is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),te-lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - lenalidomide hydrochloride monohydrate, quantity: 18.15 mg - capsule - excipient ingredients: microcrystalline cellulose; gelatin; croscarmellose sodium; indigo blue; purified talc; colloidal anhydrous silica; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm),te-lenalidomide is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),te-lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - lenalidomide hydrochloride monohydrate, quantity: 30.25 mg - capsule - excipient ingredients: microcrystalline cellulose; gelatin; titanium dioxide; colloidal anhydrous silica; purified talc; croscarmellose sodium; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm),te-lenalidomide is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),te-lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - lenalidomide hydrochloride monohydrate, quantity: 6.05 mg - capsule - excipient ingredients: microcrystalline cellulose; gelatin; colloidal anhydrous silica; purified talc; titanium dioxide; croscarmellose sodium; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm),te-lenalidomide is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),te-lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - lenalidomide hydrochloride monohydrate, quantity: 24.2 mg - capsule - excipient ingredients: purified talc; gelatin; indigo blue; croscarmellose sodium; colloidal anhydrous silica; iron oxide yellow; microcrystalline cellulose; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm),te-lenalidomide is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),te-lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - deferasirox, quantity: 360 mg - tablet, film coated - excipient ingredients: crospovidone; titanium dioxide; povidone; colloidal anhydrous silica; poloxamer; purified talc; hypromellose; microcrystalline cellulose; macrogol 4000; indigo carmine aluminium lake; magnesium stearate - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. te-deferasirox is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective.,te-deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - deferasirox, quantity: 180 mg - tablet, film coated - excipient ingredients: indigo carmine aluminium lake; purified talc; crospovidone; macrogol 4000; povidone; hypromellose; poloxamer; microcrystalline cellulose; titanium dioxide; magnesium stearate; colloidal anhydrous silica - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. te-deferasirox is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective.,te-deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - deferasirox, quantity: 90 mg - tablet, film coated - excipient ingredients: indigo carmine aluminium lake; colloidal anhydrous silica; purified talc; poloxamer; crospovidone; titanium dioxide; macrogol 4000; microcrystalline cellulose; hypromellose; magnesium stearate; povidone - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. te-deferasirox is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective.,te-deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

te arai biofarma limited - eplerenone 25mg - film coated tablet - 25 mg - active: eplerenone 25mg excipient: croscarmellose sodium hypromellose microcrystalline cellulose (type 102) lactose monohydrate magnesium stearate microcrystalline cellulose opadry white oy-l-28900 purified talc purified water sodium laurilsulfate - to reduce the risk of cardiovascular death in combination with standard therapy in patients who have evidence of heart failure and left ventricular impairment within 3 to 14 days of an acute myocardial infarction.